Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2021 | Impact of ide-cel and future directions

Nikhil Munshi • 5 May 2021
IMS 2021
Multiple Myeloma Antibodies CAR-T Ciltacabtagene autoleucel Idecabtagene vicleucel

This year we saw the FDA approval of idecabtagene vicleucel (ide-cel; formerly bb2121) for the treatment of adult patients with relapsed or refractory multiple myeloma. In this video, Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, talks on the wider impact of this approval and where he believes ide-cel will move. Specifically discussed is the use of CAR-T in combination with other therapies, and the movement of CAR-T into earlier lines of treatment. This interview took place during the 2nd Immune Effector Cell Therapy in MM Workshop in Boston, MA.

More from Nikhil Munshi

1:56
Long noncoding RNAs represent potential therapeutic targets in multiple myeloma
Nikhil Munshi • 11 Dec 2023
1:05
Alterations to the bone marrow microenvironment in patients with AL amyloidosis
Nikhil Munshi • 11 Dec 2023
2:42
Immunotherapeutic approaches to overcoming drug resistance in venetoclax-exposed patients with MM
Nikhil Munshi • 11 Dec 2023
2:02
Updated Phase I study results of PHE885 in patients with R/R multiple myeloma
Nikhil Munshi • 9 Jun 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals